Impact Biomedical Files F-4 for Zoar Limited Merger

Health

Merger Vote
IPO:
Nov 18, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Impact Biomedical Files Form F-4 Registration Statement for Proposed Merger with Zoar Limited
Houston, Texas, USA - Impact Biomedical Inc. (NYSE: IBO) announced that Zoar Limited has filed a Form F-4 registration statement with the U.S. Securities and Exchange Commission on September 10, 2026. This filing is a major milestone in connection with the previously announced business combination involving Zoar Limited, Zoar Labs Limited, and Impact Biomedical.
... Read on — Members only
About Zoar Ltd
Zoar Limited is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients and orphan drugs and provides contract development and manufacturing services to pharmaceutical and biotechnology companies worldwide. To date, Zoar Limited has shipped more than 85 pharmaceutical products to customers in 35 countries.






















